Industry Symposium
Names Will Never Hurt Me? “Antipsychotics” in the Treatment of Mood Disorders
Supported by Intra-Cellular Therapies

1. Appreciate the consequences of our current psychotropic nomenclature to optimal management and outcomes of mood disorders.
2. Evaluate the many approvals and evidence-based uses of serotonin dopamine antagonists/partial agonists (SDA-PAs) in the treatment of mood disorders.
3. Collaborate with patients and members of the care team to integrate SDA-PAs into the treatment of mood disorders in a way that optimizes acceptance, adherence, and outcomes.
4. Advocate for the widespread adoption of more appropriate and useful psychotropic nomenclature.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.